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CD40	—	a	type	I	glycosilated	phosphoglycoprotein	
with	the	molecular	weight	of	48	kDa	—	belongs	to	the	
superfamily	of	 type	 I	TNF	 receptors.	This	molecule	
was	 firstly	 identified	 on	 normal	 and	 transformed	
B-lymphocytes,	and	also	on	the	cells	of	bladder	tumor	
as	early	as	at	80th	of	last	century	[1,	].
The	discovery	of	CD40	molecules	on	normal	B-lym-
phocytes	has	encouraged	the	researches	aimed	on	the	
estimation	of	their	role	in	immunologic	response	that	
began	after	identification	of	the	ligand	for	this	molecule	
on	T-lymphocytes	—	CD40L	(CD154).	As	a	result,	it	has	
been	shown	that	CD40	and	CD40L	play	a	key	role	in	
intercellular	interactions	of	the	abovementioned	two	
main	populations	of	cells	of	immune	system	[3].	Later	
it	has	been	revealed	that	CD40	is	expressed	also	by	
a	number	of	antigen-presenting	cells	(dendritic	cells,	
monocytes,	macrophages)	eosinophils,	basophils	and	
also	by	keratinocytes,	epithelial,	neural	and	other	types	
of	cells,	and	its	expression	possesses	pronounced	co-
stimulatory	properties	[4–6].	The	structure	of	CD40	in-
cludes	extracellular,	transmembrane	and	intracellular	
parts.	The	patterns	of	CD40	structure	allow	to	suppose	
that	the	molecule	can	act	as	a	trimeric	receptor	able	
to	activate	different	messengers,	and	 its	 functional	
activity	is	manifested	at	the	highest	degree	when	CD40	
acts	as	a	trimeric	receptor	complex.	The	structure	of	
CD40	molecule	is	presented	on	the	Figure	[5].	
This	information	finally	allows	to	determine	CD40	as	
a	structure	playing	an	important	role	in	different	forms	
of	 immunologic	 response,	because	 it	 is	 taking	part	
in	activation,	proliferation,	differentiation	of	different	
types	of	cells	of	immune	system	[5,	7–9].	
ExprEssion of CD40 anD CD40L 
by DiffErEnt tumor CELLs 
During	 the	study	of	CD40	and	CD40L	 it	became	
evident	that	these	molecules	may	be	expressed	by	a	
number	of	 tumor	cells,	some	of	which	may	express	
CD40,	other	—	CD40L,	and	some	cells	—	both	mol-
ecules.	Presently	it	is	known	that	CD40	is	expressed	
by	the	cells	of	different	breast	carcinoma,	nasopha-
ryngeal,	ovarian	and	intestinal	carcinoma,	melanoma,	
glyoma,	hepatocellular	 carcinoma,	 lymphoma	etc.	
However,	whilst	 the	role	of	CD40/CD40L	 interaction	
on	 the	cells	of	 immune	system	has	been	studied	 in	
detail,	the	role	of	such	interactions	on	tumor	cells	is	
presently	under	active	study	and	has	not	been	clarified	
yet	due	to	ambiguousness	of	the	obtained	data.	For	
example,	it	has	been	demonstrated	that	CD40/CD40L	
interaction	on	many	tumor	cells	(melanoma,	different	
carcinoma,	multiple	myeloma,	 lymphoma	etc.)	may	
lead	 to	 inhibition	of	 tumor	cell	growth,	but	 in	some	
cases	may	promote	it,	too	[10–13].
The	problem	is	complicated	also	by	the	fact	that	
peculiarities	of	CD40	expression	may	be	manifested	
in	different	ways	toward	different	 lines	of	the	tumor.	
The	study	of	CD40	expression	by	the	cells	of	different	
melanoma	lines,	primary	melanoma	and	metastases	
as	well	 in	different	skin	lesions	that	precede	the	de-
velopment	of	melanoma,	allowed	to	state	a	number	of	
interesting	facts:	1)	CD40	expression	did	not	possess	
regular	character	and	in	a	number	of	cases	it	was	not	
detected	on	the	cells	of	some	lines	and	freshly	isolated	
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figure. Structure	of	CD40	type	I	isoform	(a)	and	functional	CD40	
receptor	(b)	[5]
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melanoma	cells;	 )	during	progression	of	 cancer,	
CD40	expression	has	been	decreasing;	3)	in	a	large	
number	of	cases	CD40	was	expressed	by	the	cells	of	
immunogenic	melanoma,	but	practically	never	—	by	
the	cells	of	metastases;	4)	CD40	expression	increased	
after	 stimulation	by	 IFNγ	 and	TNF,	but	not	 IL-1β	 or	
CD40L	[10].	There	are	interesting	data	showing	that	
melanoma	cells	expressing	CD40	were	able	to	mani-
fest	themselves	as	co-stimulatory	TCR	of	Т-lympho-
cytes	even	in	the	absence	of	expression	of	co-stimu-
latory	CD80	and	CD86	molecules	in	mentioned	cells.	
These	data	allowed	to	consider	CD40	as	one	of	the	
molecules,	 involved	 in	cell-mediated	stimulation	of	
CD4+Т-lymphocytes	activated	by	anti-CD3-antibod-
ies.	The	authors	of	this	work	have	demonstrated	also	
that	along	with	 stimulation	of	CD4+Т-lymphocytes,	
CD40	expression	by	melanoma	cells	may	promote	
their	proliferation	[4].
In	 another	 research,	 an	 interesting	 interpreta-
tion	of	 the	data	on	CD40	expression	by	 the	cells	of	
18	melanoma	 lines	obtained	 from	 the	patients	with	
metastasis	and	primary	tumors	has	been	presented.	In	
particular,	the	authors	observed	a	significant	percent	
of	CD40	expressing	cells	in	the	majority	of	lines,	only	
few	of	which	demonstrated	elevated	CD40	expression	
upon	 the	 influence	of	 IFNγ,	but	were	 insensitive	 for	
the	action	of	GM-CSF,	IL-	or	TNFα.	The	influence	of	
anti-CD40-antibodies	 led	 to	 increased	cell	division,	
but	did	not	elevate	B.7	expression;	these	data	allow	
to	conclude	on	the	important	role	of	CD40	in	biology	
of	melanoma	cells,	but	did	not	answer	the	question	on	
the	role	of	interaction	between	CD40	and	its	ligand	in	
antitumor	immunity	[14].
There	are	interesting	data	obtained	on	the	large	ma-
terial	and	dealing	with	the	comparative	study	of	CD40	
expression	by	the	cells	of	nevus	and	melanoma.	It	has	
been	shown	that	 in	dermoepithelial	zones	of	nevus,	
CD40	molecules	are	detected	only	in	single	cells	whilst	
in	dermal	part	they	are	not	detected	at	all.	At	the	same	
time	in	melanoma	in	a	large	majority	of	cases	CD40	
has	been	detected	with	the	intensity	dependent	on	the	
phase	of	growth;	as	a	rule,	CD40L	has	been	found	only	
in	the	cells	expressing	CD40	gene	[15].	Comparative	
evaluation	of	the	patterns	of	clinical	course	of	mela-
noma	didn’t	reveal	the	difference	between	CD40-posi-
tive	and	CD40-negative	melanocytes,	but	there	were	
found	the	differences	in	prognostic	significance	—	the	
patients	with	CD40-negative	tumors	were	character-
ized	by	shorter	survival	period.	These	results	allow	to	
consider	CD40	as	a	prognostic	marker	for	primary	skin	
melanoma,	and	simultaneous	expression	of	CD40	and	
CD40L	—	as	a	growth-promoting	factor.
As	 it	 has	 been	 shown,	CD40	 is	 expressed	 by	
normal	neural	cells,	and	in	CD40-deficient	mice	the	
dysfunction	of	neurons	accompanied	by	a	number	of	
changes,	in	particular,	morphological	ones,	elevated	
rates	of	DNA	fragmentation	and	brain	abnormalities,	
is	observed	—	the	facts	allowing	conclude	that	CD40	
molecules	play	the	role	in	the	development	of	neurons	
and	their	protection	in vitro	and	in vivo	[16].	Such	physi-
ologic	role	of	СD40	expression	by	neurons	one	should	
take	into	account	upon	evaluation	of	this	expression	
in	malignantly	transformed	cells.
The	research	of	CD40	expression	by	neuroblasto-
ma	cells	in	parallel	with	such	co-stimulatory	molecules	
as	CD80,	CD86,	B7H,	OX40L,	4-1BBL,	has	shown	
that	on	the	primary	neuroblastoma	only	some	part	of	
the	mentioned	co-stimulatory	molecules	is	expressed,	
but	CD40	was	constantly	expressed	by	the	cells	of	hu-
man	primary	neuroblastoma	and	the	cells	of	different	
lines.	Transfection	of	neuroblastoma	cells	with	 IFNγ	
gene	 leads	 to	expression	of	CD40	and	 induction	of	
apoptosis	upon	incubation	of	cells	with	recombinant	
CD40L;	the	authors	explained	the	observed	death	of	
tumor	cells	by	activation	of	caspase-8	[17].
There	 are	 the	data	 showing	 that	CD40/CD40L	
interaction	results	in	direct	inhibition	of	the	growth	of	
human	glioma	cells	in vitro.	Incubation	of	glioma	cells	
with	recombinant	sCD40L	resulted	in	CD40	expression	
on	freshly	isolated	cells	as	well	as	on	the	cells	of	one	
line	from	three	studied,	decreased	tumor	cell	viability	
and	 increased	apoptosis	 rate;	 these	data	made	 the	
grounds	to	discuss	the	possibility	of	the	use	of	sCD40L	
for	the	treatment	of	CD40-positive	glioma	[18].
Different	 breast	 carcinoma	 cells	may	 express	
CD40	and	CD40L.	The	expression	of	CD40L	on	breast	
carcinoma	cells	has	been	revealed	recently	by	Tong	
et	al.	[19].	Due	to	the	scarce	data,	presently	there	is	no	
sole	theory	on	the	role	of	expression	of	this	molecule	
[19].	The	study	of	expression	of	MHC	class	II	antigens,	
CD40,	CD80	and	CD86	 revealed	different	 levels	of	
expression	of	mentioned	molecules	on	different	breast	
carcinoma	cell	lines	[0].	The	authors	find	it	difficult	
to	evaluate	 the	biologic	meaning	of	 expression	of	
mentioned	molecules,	and	suppose	that	it	may	be	one	
of	the	reasons	of	tumor’s	escape	from	immunologic	
control	(as	it	was	mentioned	above,	analogous	point	of	
view	has	been	proposed	for	melanoma	cells,	too).
Expression	of	CD40	by	breast	 carcinoma	cells	
and	CD40/CD40L	interactions	have	been	studied	by	
other	authors,	too.	It	has	been	noted	that	incubation	
of	breast	carcinoma	cells	with	the	soluble	form	of	re-
combinant	CD40L	in vitro	led	not	only	to	inhibition	of	
cell	proliferation,	but	also	promoted	inhibiting	action	
of	IFNγ.	These	results	allowed	to	conclude	on	the	pos-
sibility	of	clinical	application	of	sCD40L	for	the	therapy	
of	breast	cancer	[1].
Upon	evaluation	of	the	role	of	CD40/CD40L	inter-
actions	on	 the	cells	of	breast	cancer	cell	 line	 it	has	
been	 revealed	 that	 transfection	of	 these	cells	with	
co-stimulatory	molecule	В.7	resulted	in	the	activation	
of	the	mechanisms	of	antitumor	defense.	Despite	the	
fact	 that	co-transfection	with	CD40	and	СD40L	was	
not	performed,	the	authors	supposed	that	the	defense	
mechanism	in	this	case	may	be	related	to	CD40/CD40L	
interaction	resulting	in	carcinoma-specific	activation	
of	TCR	[1].
To	detect	CD40	and	CD40L	expression	on	tumor	
cells,	 retrospective	analysis	of	 the	 results	of	 immu-
nohistochemical	study	of	biopsy	materials	has	been	
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performed.	 In	particular	 it	 has	been	shown	 that	 in	
cancer	of	milk	ducts	and	lobular	form	in	the	majority	
of	cases	CD40	expression	was	registered.	CD40L	was	
expressed	at	various	 levels	more	often	 in	 infiltrating	
forms	of	cancer	 than	 in	carcinoma	 in situ.	 Tumors	
were	infiltrated	by	lymphocytes,	the	majority	of	which	
were	expressing	CD40,	whilst	the	minority	—	CD40L.	
That’s	why	the	authors	concluded	that	 lymphocytes	
infiltrating	the	primary	tumor	could	possess	a	limited	
capacity	to	modulate	directly	tumor	growth	by	CD40/
CD40L	interaction	[19].
Expression	of	CD40	has	been	 found	also	on	 the	
cells	of	other	epithelial	 tumors.	The	study	of	ovar-
ian	cancer	cells	(cell	lines	as	well	as	freshly	isolated	
tumor	cells)	has	shown	that	 the	cells	of	all	 lines	are	
expressing	CD40,	and	CD40	mRNA	was	revealed	 in	
each	primary	sample	thus	pointing	that	it	may	occur	
in vivo	as	well	[].	The	high	rate	of	the	presence	of	
CD40	in	ovarian	cancer	cells	allows	to	conclude	that	
this	molecule	may	be	used	as	a	target	for	the	therapy	
of	ovarian	cancer.
Expression	 of	CD40	 at	 different	 levels	 and	 its	
dependence	on	cytokine	action	has	been	observed	
in	 the	cells	of	human	hepatocellular	carcinoma	and	
squamous	cell	carcinoma	of	head	and	neck.	In	the	first	
case	the	level	of	CD40	expression	was	extremely	low,	
so	the	authors	did	not	find	it	reasonable	to	evaluate	its	
influence	on	hepatocellular	carcinoma	cells.	Moreover,	
according	to	the	obtained	data,	CD40/CD40L-interac-
tion	did	not	affect	the	viability	of	hepatoma	cells	and	
the	expression	of	co-stimulatory	molecules	CD54,	
CD80,	CD86	and	CD5	[3].
The	 study	of	CD40	expression	 the	cells	 of	 hu-
man	squamous	cell	carcinoma	of	head	and	neck	has	
shown	that	the	cells	of	all	lines	expressed	CD40,	EGF	
receptor,	MHC	class	I	antigens,	CD95,	but	constant	
expression	of	such	 important	 regulatory	molecules	
as	CD80,	CD86,	CD5	wasn’t	observed.	Analyzing	
the	obtained	results,	the	authors	have	concluded	that,	
firstly,	CD40	is	a	molecule	regulating	the	growth	of	the	
cells	of	squamous	cell	carcinoma,	and	secondly,	that	
CD40/CD40L	 interaction	plays	an	 important	 role	 in	
regulation	of	immunocompetent	cells	of	lymph	nodes,	
and	high	level	of	CD40L	expression	allows	hypothesize	
that	such	ligand-receptor	interactions	are	important	
mediators	of	the	growth	of	squamous	cell	carcinoma	
cells	[4].
The	abovementioned	data	are	evidencing	on	ability	
of	tumor	cells	of	different	histogenesis	(mainly	mes-
enchymal	and	epithelial)	and	localization	to	express	
CD40	and	CD40L.	The	reported	data	are	showing	also	
that	in	the	majority	of	cases	CD40/CD40L	interactions	
on	tumor	cells	leads	to	inhibition	of	tumor	growth,	but	
in	 some	cases	CD40/CD40L	 interaction	may	have	
stimulating	effect	as	well.	That’s	why	it	 is	difficult	to	
evaluate	biological	role	of	CD40	and	CD40L	expres-
sion	by	tumor	cells.	Naturally,	a	number	of	questions	
appears,	at	the	first	hand,	the	next	ones:	1)	Why	some	
tumors	express	CD40,	the	other	ones	—	CD40L,	and	
the	 third	ones	—	both	molecules?	)	Why	 the	cells	
originated	from	the	same	tumor	vary	in	CD40	expres-
sion	 level?	3)	What	are	the	conditions	promoting	an	
interaction	of	CD40-positive	tumor	cells	with	the	cells	
of	immune	system?	4)	Why	CD40/CD40L	interaction	
may	influence	tumor	growth	in	different	ways?	To	an-
swer	these	questions,	one	should	take	into	account	
that	CD40	may	affect	tumor	cell	proliferation	[5],	and	
such	influence	may	manifest	itself	in	dependence	on	
the	properties	of	tumor	cells	and	microenvironment.	
These	questions	as	well	as	other	ones	should	be	stud-
ied	 further,	and	presently	 there	are	numerous	data	
allowing	to	explain	some	mechanisms	of	the	influence	
of	CD40/CD40L	interaction	on	tumor	growth.
inhibition of tumor growth 
upon infLuEnCE of CD40/CD40L 
intEraCtion 
The	decisive	fact	of	tumor	growth	inhibition	due	to	
CD40/CD40L	 interaction	on	 tumor	cells	expressing	
the	mentioned	molecules	has	open	a	question	on	the	
mechanisms	of	such	inhibiting	influence.	Analysis	of	
the	literature	data	on	this	topic	allows	to	conclude	that	
there	are	two	main	mechanisms	of	such	influence	on	
tumor	growth.	The	first	one	is	the	induction	of	different	
immunologic	processes	participating	in	antitumor	de-
fence,	and	the	second	one	is	an	induction	of	apoptosis.	
The	study	of	mentioned	mechanisms	has	shown	that	
each	of	them	may	result	from	the	activation	of	numer-
ous	processes,	i.e.	be	multifactorial.
immunoLogiC mEChanisms
As	 it	 is	known,	 the	central	place	 in	 the	 induction	
of	 specific	 antitumor	 immunity	 is	 occupied	by	 the	
activation	of	antigen-presenting	cells,	 in	particular	
dendritic	cells,	monocytes,	B-lymphocytes	which,	as	
a	rule,	express	CD40.	Exactly	these	cells	are	providing	
the	first	and	the	most	important	stage	of	immunologic	
response	—	recognition	of	tumor	antigens.	
In	the	study	of	processes	of	recognition	a	lot	of	at-
tention	is	devoted	to	professional	antigen-presenting	
dendritic	cells.	There	is	a	sufficient	amount	of	data	on	
the	favourable	influence	of	CD40/CD40L	interactions	
on	the	functions	of	dendritic	cells,	the	disturbance	of	
which,	as	it	 is	known,	happens	often	upon	the	influ-
ence	of	different	suppressing	substances	produced	by	
tumor	cells	[6].	Using	breast	cancer	cells,	it	has	been	
demonstrated	that	CD40-ligation	protects	circulating	
dendritic	cells	 from	apoptosis	caused	by	 the	action	
of	 such	substances,	by	 induction	of	expression	of	
antiapoptotic	molecule	Bcl-	[7].	Moreover,	at	these	
conditions	not	only	 the	protection	of	dendritic	cells	
from	apoptosis	 is	 taking	place,	but	 the	 functions	of	
populations	of	immature	dendritic	cells	are	promoted.	
It	is	of	significance	also	that	the	activation	of	dendritic	
cells	is	accompanied	by	the	elevation	of	IL-1	and	INFγ	
production	and	enhanced	cytotoxicity	of	killer	cells.	
Intracellular	mechanism	of	CD40	activation	is	accom-
panied	by	the	activation	of	a	number	of	transcriptional	
factors	of	protein	origin,	and	this	process	occurs	with	
the	involvement	of	Toll-like-receptors	[7].	
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Activation	of	dendritic	cells	is	possible	not	only	due	
to	the	interaction	of	recombinant	CD40L	or	anti-CD40-
antibodies,	but	also	via	interaction	with	tumor	cells	ex-
pressing	CD40L.	It	has	been	proved	in	experiments	on	
ovarian	carcinoma	cells	transfected	with	CD40L	gene	
with	the	use	of	adenoviral	vector.	Upon	interaction	of	
these	cells	with	dendritic	cells	of	peripheral	blood,	
IL-1	production	by	dendritic	cells	was	elevated	[9].	
For	induction	of	immunologic	response	it	is	impor-
tant	to	account	that	activation	of	CD40,	expressed	by	
macrophages and monocytes,	is	accompanied	by	
their	stimulation	and	activation	of	numerous	 immu-
nologic	mechanisms.	For	example,	 intraperitoneal	
administration	of	anti-CD40-antibodies	activates	mac-
rophages	that	acquire	ability	to	suppress	proliferation	
of	melanoma	B-16	cells;	after	such	activation	macro-
phages	begin	to	produce	INFγ	 [8].	Further	studies	
of	 these	authors	have	shown	 that	 the	activation	of	
CD40	 leads	 to	 increased	expression	of	 intracellular	
Toll-like-receptor	(TLR9)	in	macrophages	—	the	fact	
evidencing	on	 involvement	 of	 this	 receptor	 in	 the	
process	of	activation	of	macrophages	at	mentioned	
conditions	[9].	
Stimulation	of	CD40	by	anti-CD40-antibodies	or	
soluble	form	of	CD40L	(sCD40L)	enhances	also	the	
activity	of	monocytes,	 in	particular	 in	cervical	 car-
cinoma	cells.	This	process	is	based	on	activation	of	
NFkappa-B	and	MARK-dependent	pathways,	 that	
leads	to	elevation	of	expression	of	surface	molecules	
and	activation	of	a	number	of	intracellular	processes	
related	to	antigen	presentation	and	processing	[30].	
CD40/CD40L	interaction	plays	an	important	role	on	
b-lymphocytes,	too;	it	is	known	that	such	interaction	
promotes	their	proliferation,	differentiation,	increases	
the	 level	of	expression	of	co-stimulatory	molecules	
and	elevates	antigen	presentation	[31].	Interaction	of	
CD40L	with	B-lymphocytes	 loaded	with	 tumor	pep-
tides	 is	capable	 to	 induce	antitumor	 immunity.	This	
statement	has	been	proved	by	experiments	using	
intravenous	administration	of	CD40L	to	mice,	whose	
В-lymphocytes	were	 loaded	by	peptides	—	 tumor	
antigens	presented	by	HLA	class	 I	antigens	[3].	At	
such	conditions	 tumor	growth	 retardation	has	been	
observed.	As	a	result	of	activation	of	B-lymphocytes	
upon	the	influence	of	CD40L,	an	induction	of	specific	
T-cell	response	occurs,	that	(by	opinion	of	the	authors)	
develops	due	 to	 the	direct	 influence	on	B-lympho-
cytes,	and	cross	one	—	on	resident	antigen-present-
ing	cells.
Stimulation	of	CD40	on	tumor	cells	is	not	limited	by	
the	activation	of	antigen-presenting	cells	and	includes	
also	other	cells	of	immune	system	that	participate	at	
the	further	stages	of	the	development	of	immunologic	
response.	Presently	it	is	known	that	activation	of	CD40	
leads	 to	 stimulation	of	cytotoxic t-lymphocytes 
(CtL), memory t-lymphocytes, natural killer 
cells (nK).	
After	transfection	of	CD40L	gene	in	multiple	my-
eloma	cells	active	generation	of	specific	CTL	and	the	
tendency	to	increased	Th1-cell	response	is	observed	
[33].	There	are	interesting	results	of	the	studies	car-
ried	out	on	cell	lines	of	different	carcinoma	(bladder,	
pancreatic,	breast	carcinoma	and	melanoma)	express-
ing	CD40.	The	treatment	of	the	cells	with	recombinant	
CD40L	or	anti-CD40-antibodies	was	accompanied	by	
expression	of	ICAM,	Fas-antigen	on	tumor	cells,	and	
stimulated	production	of	IL-6,	IL-8,	GROα,	GM-CSF	
and	TNFα,	whilst	incubation	of	CD40-positive	tumor	
cells	with	CD40L	or	anti-CD40-antibodies	 leads	 to	
significant	 inhibition	of	 tumor	cell	proliferation,	dis-
turbance	of	cell	cycle	and	decreased	viability	of	the	
cells.	On	the	base	of	obtained	data,	the	authors	have	
concluded	that	the	presence	of	CD40	on	carcinoma	
cells	may	be	considered	as	an	important	factor	of	in-
duction	of	tumor-specific	T-cell	response	[34].	
Activation	of	T-cell	specific	antitumor	response	is	
taking	place	also	upon	transfection	of	dendritic	cells	
with	CD40L;	 in	 these	conditions	CD4+-	and	CD8+Т-
lymphocytes	are	activated	[35].
Ligation	of	CD40	 induces	antibody-dependent	
cytotoxicity	of	NK	CD56+CD3-cells.	Using	multiple	my-
eloma	cells	expressing	CD40,	it	has	been	shown	that	
action	of	humanizated	anti-CD40-antibodies	(SGN-40)	
on	these	cells	mediates	antibody-dependent	cytotox-
icity	against	myeloma	cells	via	suppression	of	 IL-6-
dependent	proliferation	and	apoptosis	[36].
From	the	mentioned	data	one	may	conclude	that	
CD40/CD40L	 interaction	on	 tumor	cells	manifests	
itself	by	activation	of	different	cells	of	immune	system	
involved	in	antitumor	defence.
apoptotiC mEChanisms
The	study	of	biologic	role	of	CD40/CD40L	interac-
tion	allowed	to	obtain	the	data	evidencing	on	the	fact	
that	along	with	its	positive	influence	on	the	functions	
of	cells	of	immune	system,	it	may	take	part	in	induc-
tion	of	apoptosis.	Such	 results	have	been	obtained	
in	the	studies	of	tumor	cells	of	different	etiology	and	
histogenesis	[5,	37,	38].	Then	the	question	is	rised	on	
the	mechanisms	of	CD40/CD40L-induced	apoptosis.	
The	important	studies	carried	in	parallel	on	normal	and	
transformed	cells	have	shown	that	upon	activation	of	
CD40,	apoptosis	is	observed,	as	a	rule,	in	malignant	
cells	but	not	in	normal	ones	[5,	39,	40].	Then	the	next	
question	appeared	—	how	 these	differences	could	
be	explained?	Unfortunately,	presently	this	question	
remains	unanswered,	but	some	facts	allow	to	explain	
the	phenomenon	in	part.	
As	it	was	revealed,	different	apoptotic	stimuli	influ-
ence	different	genes	in	normal	and	transformed	cells.	
For	example,	the	study	of	normal	keratinocytes	and	
oral	cancer	cells	of	Tu183	line	has	shown	that	upon	
action	of	different	proapoptotic	stimuli,	expression	
of	different	proapoptotic	genes	occurs	as	well	as	the	
gene	coding	for	CD40	[40].
The	study	of	normal	and	malignantly	transformed	
epithelial	cells	of	urinary	tract	has	demonstrated	that	
upon	 interaction	of	malignant	 cells	with	mCD40L,	
but	not	sCD40L	quick	elevation	and	stabilization	of	
TNF-associated	 factor	3	 (TRAF-3)	and	activation	of	
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caspases-9	and	-3	is	taking	place.	Contrary	to	this,	in	
normal	cells	CD40L	is	not	inducing	apoptosis	but	leads	
to	quick	decrease	of	activity	of	TRAF-3	and	TRAF-	
[39].	These	data	are	of	interest	because,	firstly,	they	
demonstrate	the	differences	in	molecular	mechanisms	
of	 influence	of	mCD40L	on	normal	and	transformed	
cells,	and	secondly,	they	reveal	a	new	way	for	mCD40L-
induced	apoptosis.	According	 to	 recently	published	
data,	another	 factor	associated	with	TNF-receptor	
family	may	decrease	proliferation	and	promote	apop-
tosis	of	myeloma	cells,	—	TRAF-6	[41].	The	authors	
consider	 this	 factor	as	a	new	molecular	 target	 for	
blocking	signal	transduction	necessary	for	survival	and	
proliferation	of	the	cells	of	multiple	myeloma.
The	 functional	meaning	of	СD40	expression	on	
normal	 and	 transformed	cells	 of	 urinary	 tract	 has	
been	studied	also	by	other	authors.	 In	experiments	
the	cells	were	incubated	with	CD40L,	TNFα	and	anti-
Fas-antibodies;	it	has	been	shown	that	CD40L	leads	
to	apoptosis	of	transformed	cells,	but	not	of	normal	
cells	where	induction	of	apoptosis	requires	the	pres-
ence	of	other	TNFR-agonists.	It	has	been	noted	that	
the	decrease	of	expression	 level	of	CD40	could	be	
considered	as	an	important	mechanism	of	the	devel-
opment	and	progression	of	carcinoma	[4].	
The	evidence	on	possibility	to	induce	apoptosis	at	
the	conditions	of	CD40	activation	was	demonstrated	
by	many	authors	who	have	shown	 that	 the	different	
mechanisms	could	be	involved	in	this	process.	In	early	
publications	it	was	shown	that	CD40/CD40L-induced	
apoptosis	may	occur	with	the	involvement	of	caspase-
dependent	and	caspase-independent	mechanisms.	
In	 particular,	 the	development	 of	 apoptosis	 upon	
activation	of	CD40	on	multiple	myeloma	cells	was	not	
associated	with	DNA	 fragmentation	and	enhanced	
CD95	expression	[37].	
Ability	of	CD40/CD40L	 interaction	 for	 induction	
and	modeling	of	CD95-dependent	 apoptosis	 has	
been	demonstrated	on	neuroblastoma	that	is	known	to	
possess	the	decreased	level	of	expression	of	antigens	
HLA	classes	I	and	II;	upon	the	influence	of	recombinant	
CD40L	apoptosis	is	induced	via	caspase-8-dependent	
mechanism	[43].
The	study	of	squamous	cell	carcinoma	of	head	and	
neck	has	demonstrated	that	CD40-ligation	decreased	
the	rate	of	cell	proliferation	by	induction	of	spontane-
ous	and	Fas-induced	apoptosis	and	also	EGFr-depen-
dent	inhibition	of	proliferation	[44].
There	are	also	the	data	evidencing	that	CD40-liga-
tion	is	not	related	to	development	of	CD95-mediated	
apoptosis.	In	the	study	of	different	ovarian	cancer	cells	
(conserved	and	 freshly	 isolated	ones,	 from	primary	
and	secondary	tumors)	it	has	been	stated	that	there	
are	the	differences	in	the	levels	of	CD40	expression	
between	ascitic	cells	and	cells	from	solid	forms	as	well	
as	between	primary	and	secondary	tumors	[38].	
It’s	 interesting	 to	note	 that	despite	 the	 fact	 that	
CD40	belongs	to	the	family	of	TNF-receptors,	CD40/
CD40L	interaction	is	accompanied	only	with	activation	
of	PI3k/Akt-signal	cascade,	but	not	NFkappa-B	activa-
tion	contrary	to	other	members	of	the	family	[45].
CD40/CD40L	interaction	may	play	a	role	not	only	
in	solid	 tumors	but	 lymphoproliferative	diseases	as	
well,	in	particular	B-cell	chronic	lymphocytic	leukemia	
a	number	of	which	express	IL-1	receptor.	Expression	
of	this	receptor	 is	associated	with	the	expression	of	
CD40,	and	upon	 the	 influence	of	 IL-1	 in	 the	cells	
of	B-cell	chronic	 lymphocytic	 leukemia,	caspases	8	
and	3	are	activated,	proliferation	 is	suppressed	and	
apoptosis	is	induced	[46].	The	authors	consider	these	
facts	as	a	new	mechanism	of	regulation	of	the	balance	
between	cell	survival	and	death	of	B-lymphocytes	at	
chronic	lymphoid	leukemia.	
Summarizing	 the	mentioned	above	data	on	 the	
mechanism	of	 inhibiting	 influence	of	CD40/CD40L	
interaction	on	tumor	growth,	one	may	conclude	that	
these	data	are	convincing.	However,	one	should	take	
into	account	 the	point	of	view	of	some	authors	who	
suppose	that	the	inhibition	of	tumor	growth	resulting	
from	CD40/CD40L	interaction	in	many	cases	may	be	
caused	by	combined	effect	including	an	induction	of	
apoptosis	and	stimulation	of	immunologic	processes	
starting	from	recognition	of	tumor	antigens	[5,	30].
stimuLation of tumor growth upon 
CD40/CD40L intEraCtion
As	it	was	mentioned	above,	in	many	cases	CD40/
CD40L	interaction	leads	to	inhibition	of	tumor	growth.	
Along	with	this,	there	are	also	some	data	that	evidence	
on	CD40/CD40L	 interaction	 that	may	result	 in	 tumor	
growth	stimulation.	The	study	of	the	phenomenon	of	
such	stimulation	is	important	because	firstly	it	is	neces-
sary	to	determine	the	methodology	of	the	therapy	based	
on	CD40	activation.	The	data	on	this	topic	are	scarse,	
and	indicate	that	different	mechanisms	may	be	involved	
in	tumor	growth	stimulation	upon	CD40	activation.	
One	 of	 such	mechanisms	 is	 the	 secretion	 of	
cytokines	promoting	 tumor	growth.	 In	 the	study	of	
multiple	myeloma	cells,	the	elevation	of	secretion	of	
VEGF	—	active	factor	of	angiogenesis	—	has	been	ob-
served	in	parallel	with	increased	migration	of	myeloma	
cells,	thus	indicating	the	role	of	CD40	in	regulation	of	
their	homing	and	angiogenesis.	Comparative	study	of	
different	myeloma	cell	lines	expressing	wide	type	p53	
and	mutant	ones	has	shown	that	VEGF	expression	was	
significantly	higher	in	the	cells	expressing	mutant	p53	
gene	pointing	on	participation	of	 the	gene	 in	VEGF	
secretion	[36,	47].
There	are	the	data	demonstrating	that	stimulation	
of	tumor	growth	upon	CD40	activation	may	be	caused	
by	production	of	IL-6.	These	data	were	obtained	in	the	
research	of	myltiple	myeloma	cells	expressing	CD40,	
and	plasmatic	cells	of	leukemia	and	stromal	cells.	Trans-
fection	of	myeloma	cells	with	CD40L	gene	leads	to	the	
increased	IL-6	secretion	by	these	cells	and	stimulation	
of	cell	growth	 in	autocrine	or	paracrine	 fashion	[48].	
Possible	participation	of	cytokines	 in	 tumor	growth	
stimulation	has	been	noted	by	many	authors	[49].	
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Tumor	growth	stimulation	upon	CD40	activation	
may	occur	also	via	elevation	of	heterotypic	and	homo-
typic	adhesion.	 In	the	research	of	myltiple	myeloma	
cells	such	stimulation	was	associated	with	the	expres-
sion	of	a	number	of	surface	structures	and	transloca-
tion	of	86	kDa	subunit	of	Кu-antigens	involved	in	cell	
adhesion	[48,	50].
There	are	important	data	on	the	ability	of	CD40-ac-
tivation	to	stimulate	multiple	drug	resistance	that	were	
obtained	in	the	study	of	non-Hodgkin’s	lymphoma	cells	
and	breast	cancer	cells.	According	to	the	data,	CD40L	
induced	multiple	drug	 resistance	 (to	doxorubicine,	
etoposide,	vinblastin	etc.)	in	mentioned	cells	by	dif-
ferent	ways:	in	non-Hodgkin’s	lymphoma	cells	—	by	
caspase-dependent	and	 -independent	ways,	while	
in	breast	cancer	cells	—	only	by	caspase-dependent	
one.	In	the	next	studies	on	non-Hodgkin’s	lymphoma	
cells	and	carcinoma	cells	co-cultivated	with	 irradi-
ated	CD40-positive	L-cells	it	has	been	shown	that	in	
carcinoma	 cells	 caspase-independent	 apoptosis	
is	 realized,	while	 in	non-Hodgkin’s	 lymphoma	cells	
the	activity	of	caspases-5-7	was	elevated	manifold	
compared	to	the	 initial	 level.	The	negative	 influence	
of	CD40	activation	has	been	proved	by	the	fact	that	
the	treatment	with	anti-CD40-antibodies	prevents	the	
development	of	drug	resistance	[51,	5].
Using	gastric	carcinoma	cells	 it	has	been	shown	
that	activation	of	CD40	with	soluble	 form	of	CD40L	
significantly	inhibits	Fas-dependent	and	drug-induced	
apoptosis	and	also	 increases	 the	motility	of	CD40-
positive	 tumor	 cells,	 that	 finally	 leads	 to	 elevated	
survival	of	gastric	carcinoma	cells	[53].	
It	has	been	demonstrated	that	 the	stimulation	of	
bladder	carcinoma	cells	expressing	CD40	with	CD40L	
protects	 the	cells	 from	apoptosis	and	 increases	the	
survival	rate,	and	the	mechanism	of	cell	growth	stimu-
lation	is	related	to	the	decrease	of	CD95-dependent	
apoptosis	[54].	
Incubation	of	lung	cancer	cells	of	A549	line	express-
ing	CD40	with	sCD40L	results	in	high	level	expression	
of	CD54,	TNFR1	and	CD95L.	The	authors	have	noticed	
that	such	effect	is	dependent	in	large	part	on	the	phase	
of	cell	cycle,	and	concluded	that	sCD40L	may	inhibit	
proliferation,	alter	phenotype	of	A549	cells	and	disturb	
the	expression	of	apoptosis-associated	genes,	in	par-
ticular	these	controlling	expression	of	Bax	[55].
Stimulation	of	cell	growth,	elevated	cell	 survival	
and	neovascularization	have	been	registered	also	on	
sarcoma	Kaposi	cells	treated	with	anti-CD40-antibod-
ies;	moreover,	 the	 induction	of	 tumor	cell	migration	
and	 inhibition	of	 vincristin-induced	apoptosis	were	
shown,	too	[56].	
Activation	of	CD40	may	lead	to	inhibition	of	apop-
tosis	with	 the	 involvement	of	another	caspase-de-
pendent	mechanism	mediated	by	PPAR	receptor	and	
activation	of	NFkappa-B,	as	 it	 has	been	shown	on	
murine	B-lymphoma	cells	of	WEHI-31	line	[57].
Concluding	the	abovementioned	data,	one	could	
state	that	activation	of	CD40	may	lead	to	tumor	growth	
stimulation	by	different	ways.	This	fact	is	showing	that	
CD40	expression	like	that	of	other	surface	structures	
of	tumor	cells	(cytokine	receptors	etc.)	may	manifest	
itself	 in	dependence	on	 the	properties	of	 the	 tumor	
and	tumor	microenvironment.
nEw approaChEs to immunothErapy 
basED on CD40/CD40L intEraCtion
Despite	incomplete	knowledge	on	biologic	role	of	
CD40	expression	on	tumor	cells	and	influence	of	its	
activation	on	tumor	growth,	the	large	part	of	data	are	
evidencing	on	its	potential	role	as	a	target	for	cancer	
immunotherapy.	The	data	about	negative	influence	of	
CD-40	ligation	may	be	used	as	well	for	the	develop-
ment	of	means	for	its	blocking.	
As	it	was	mentioned	above,	CD40/CD40L	interac-
tion	 leads	 to	 induction	of	different	mechanisms	of	
antitumor	defence;	 the	development	of	means	 for	
immunotherapy	 is	based	exactly	on	 these	mecha-
nisms.	Presently	there	are	the	next	ways	based	on	the	
activation	of	CD40/CD40L	interaction:	1)	stimulation	
of	antigen-presenting	cells;	)	 induction	of	CD40/
CD40L	interaction	on	the	surface	of	tumor	cells	and	
their	gene-engineering	modification;	3)	preparation	of	
the	vaccines	on	the	base	of	CD40/CD40L	interaction;	
4)	combination	of	CD40	activation	with	other	 thera-
peutical	approaches.	
Activation of CD40 on antigen-presenting cells
From	the	above	mentioned	reports	one	may	con-
clude	that	activation	of	immune	system	cells,	mainly	
antigen-presenting	ones,	has	been	performed	in	dif-
ferent	ways:	influence	of	CD40L	or	anti-CD40-antibod-
ies	and	gene-engineering	modification	of	dendritic	
cells	with	the	use	of	different	viral	vectors.	In	a	large	
number	of	studies,	the	authors	have	observed	tumor	
growth	inhibition	and	have	concluded	that	the	reported	
facts	are	providing	rationale	for	clinical	application	of	
such	approach.	In	particular,	such	data	were	obtained	
in	the	studies	of	different	tumors	—	neuroblastoma,	
breast	cancer,	cancer	of	head	and	neck,	melanoma	
[7,	9,	44,	58,	59].
For	activation	of	antigen-presenting	cells	human-
izated	anti-CD40-antibodies	(SGN-40)	are	used.	For	
example,	the	treatment	of	human	multiple	myeloma	
cells	of	different	lines	has	been	shown	to	significant	
increase	of	 apoptosis	 rate	and	decreased	expres-
sion	of	IL-6	receptor.	The	authors	supposed	that	the	
results	are	making	grounds	for	clinical	application	of	
SGN-40	[36].
Transfection	of	immature	dendritic	cells	with	CD40L	
using	adenoviral	vector	promoted	their	maturation	and	
elevated	 the	cytotoxicity	of	CD4+Т-lymphocytes	with	
killer	activity.	Such	vaccine	 introduced	 intratumorally	
or	 in	distant	sites	sharply	suppressed	 the	growth	of	
myeloma	[33].
Induction of CD40/CD40L interaction on the 
surface of tumor cells and their gene-engineer-
ing modification 
The	efficacy	of	such	approach	for	 immunotherapy	
has	been	proved	by	the	studies	carried	on	different	mod-
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els:	small	cell	lung	cancer,	cervical,	gastric,	and	bladder	
cancer,	prostate	adenocarcinoma	[30,	54,	60].
After	 transfection	of	rat	adenocarcinoma	cells	of	
TRAMP-CD	 line	with	CD40L	gene	using	adenoviral	
vector,	the	derease	of	tumor	cell	viability	and	induction	
of	apoptosis	has	been	observed	 in vitro	and	 in vivo,	
allowing	to	conclude	on	the	perspectiveness	of	such	
therapy	approach	[61].
Introduction	of	CD40L	gene	in	tumor	cells	(mas-
tocytoma	Р815)	potentiated	 the	activity	of	dendritic	
cells,	accelerated	their	maturation,	induced	antitumor	
defence	pointing	on	the	possibility	to	use	this	approach	
for	anticancer	gene	therapy	[6].
Similarly,	introduction	of	blastoma	cells	transfected	
with	CD40L	gene	using	retroviral	vector	resulted	in	de-
creased	tumor	volume	in vivo,	increase	of	the	number	
of	CD4+-	and	CD8+Т-lymphocytes	as	well	as	elevated	
survival	of	animals	[63].	The	authors	have	noted	that	
after	 administration	 even	of	 low	 amount	 of	 these	
modified	tumor	cells,	prolonged	systemic	antitumor	
immunity	has	been	preserved.
Preparation of vaccines on the base of CD40/
CD40L interaction
As	 it	 is	known,	 the	use	of	dendritic	cells	 loaded	
with	tumor	peptides,	tumor	cell	lyzates,	RNA,	apop-
totic	 tumor	cells,	or	gene-engineering	modification	
of	dendritic	cells	is	presently	considered	as	the	most	
perspective	 immunotherapeutical	 approach	 [64].	
This	approach	consideres	 the	use	of	dendritic	cells	
loaded	with	tumor	antigens	upon	activation	of	CD40,	
and	some	experience	of	preparation	and	application	
of	such	vaccines	has	been	accumulated.	
The	use	of	dendritic	cells	or	monocytes	loaded	with	
tumor	peptides	 (MART-1/MelanA)	and	 transfected	
with	CD40L	was	accompanied	by	expression	of	co-
stimulatory	molecules,	 elevation	of	 immunogenic	
properties	of	tumor	peptides	and	generation	of	cyto-
toxic	CD8+Т-lymphocytes	[35].
Using	mastocytoma	Р815	model	it	has	been	shown	
that	immunization	of	animals	with	bone	marrow	acti-
vated	dendrititc	cells	 loaded	with	tumor	peptides	of	
mastocytoma	 (Р198	and	PIA)	promoted	 interaction	
with	CD40L	 cytotoxic	 Т-lymphocytes	 (fibroblasts	
transfected	with	CD40L	gene	were	used	as	a	source	
of	CD40L-signal).	Taking	into	account	the	pronounced	
antitumor	response,	the	authors	have	concluded	that	
vaccination	with	dendritic	cells	could	be	applied	on	
clinical	practice	[65].
If	dendritic	cells	transfected	with	melanoma	antigen	
MART-1	using	adenoviral	vector	were	administered	to	
melanoma-bearing	mice,	an	accelerated	maturation	
of	dendritic	cells	and	an	induction	of	CTL-dependent	
antitumor	defence	has	been	observed	[66].
CD40/CD40L-interaction	may	play	an	important	role	
in	realization	of	effects	of	vaccines	from	tumor	peptides.	
In	these	cases	the	therapeutical	effect	is	provided	by	the	
involvement	of	cytotoxic	T-lymphocytes,	thus	making	
grounds	for	use	of	CD40-stimulating	agents	as	com-
ponents	of	antitumor	vaccines	[67].
Another	promising	approach	is	the	use	of	antitu-
mor	vaccine	with	autologic	 tumor	cells	 transfected	
with	recombinant	CD40L	[68],	and	it	is	supposed	that	
the	use	of	such	vaccine	 is	excluding	 the	 risk	of	 the	
development	of	autoimmune	pathology	and	could	be	
proposed	for	clinical	application.
For	vaccine	preparation	one	could	use	also	CD40L-
activated	В-lymphocytes	loaded	with	tumor	peptides	
that	are	presented	by	antigens	MHC	class	I,	and	stimu-
lating	different	immunologic	mechanisms	[Ritchie].
At	last,	the	approach	based	on	the	use	of	B-lym-
phocytes	 from	peripheral	blood	of	healthy	donors,	
stimulated	by	CD40/CD40L-interaction	and	 loaded	
with	 tumor	 antigens	 should	be	mentioned.	 These	
B-cells	possess	strongly	elevated	antigen-present-
ing	patterns.	Such	vaccine	was	obtained	with	the	use	
of	melanoma	antigens	or	melanoma	cell	lyzates,	and	
pronounced	promotion	of	presentation	of	the	antigens	
with	involvement	of	MHC	class	II	antigens	to	CD4+Т-
lymphocytes	was	observed	[69].	
Combination of CD40 activation with other 
therapeutical approaches
In	recent	years	there	is	a	number	of	reports	on	high	
efficacy	of	combination	of	activation	of	CD40/CD40L	
interaction	with	other	therapies.	The	most	promising	
is	 its	combination	with	chemotherapy.	For	example,	
activation	of	CD40	in	a	complex	with	nucleoside	analog	
hemcytavine	has	been	used	for	treatment	of	different	
solid	tumors.	In	these	conditions	it	resulted	in	an	ex-
pansion	of	CD8+Т-lymphocytes,	whilst	chemotherapy	
promoted	cellular	antitumor	immunity	[3].
Preincubation	 of	murine	 breast	 cancer	 cells	
transfected	with	CD40L	using	adenoviral	vector,	with	
carboplatine	significantly	elevated	antitumor	effect	
compared	to	that	for	modified	tumor	cells	only	[9].
CD40/CD40L	interaction	was	shown	to	occupy	an	
important	place	also	 in	 the	case	of	vaccination	with	
irradiated	melanoma	cells	and	adjuvants	[70].
A	number	of	studies	proved	an	efficacy	of	CD40-
activation	 in	 the	 combination	with	other	 immuno-
therapy	approaches	 (immunomodulators,	adoptive	
LAK-therapy).	 For	 example,	 the	 combined	use	of	
humanizated	anti-CD40-antibodies	along	with	immu-
nomodulator	lenalidomide	(pretreatment	of	myeloma	
cells	with	this	immunomodulator)	promoted	the	lyzis	
of	autologous	cells	of	multiple	myeloma	and	restored	
the	sensitivity	of	resistant	myeloma	cells	[36].
Promotion	of	antitumor	effect	upon	CD40-activa-
tion	has	been	observed	also	in	the	case	of	administra-
tion	of	oligonucleotide	 immunomodulator	CpG,	 that	
was	accompanied	by	 increased	production	of	 INFγ,	
IL-1,	NO	by	macrophages	in	parallel	with	elevation	of	
their	cytotoxic	action	leading	to	inhibition	of	growth	of	
melanoma	В16;	activation	occurred	upon	interaction	of	
CD40-positive	tumor	cells	and	TLR9	of	macrophages.	
The	efficacy	of	such	therapy	has	been	documented	
in vivo	even	upon	 the	development	of	 immunologic	
insufficiency	[8,	9].
There	is	an	interesting	study	on	a	new	strategy	for	
combined	use	of	dendritic	cells	and	LAK	(activation	
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with	IL-	or	anti-CD3-antibodies),	based	on	co-cultiva-
tion	of	dendritic	cells	and	LAK	isolated	from	peripheral	
blood	of	the	patients	with	metastases	and	expressing	
CD40L;	 such	approach	significantly	 increased	 the	
activity	of	dendritic	cells	which	antigen-presenting	
capacity	was	elevated	two	fold	[71].	One	should	note	
that	the	effect	has	been	achieved	without	gene	modi-
fication	and	application	of	monoclonal	antibodies.	
Combined	use	of	CD40	and	cytokines	may	be	
considered	as	well.	In	a	series	of	studies	performed	by	
Murphy	et	al.	[7],	the	data	on	efficacy	of	the	combined	
use	of	CD40	activation	and	IL-	were	reported.	The	
combined	use	of	IL-	and	CD40	activation	was	shown	
to	be	effective	also	 in	 the	 influence	on	hemopoietic	
cells	—	 it	has	been	shown	 in vivo	on	chimeric	mice	
carrying	transplanted	renal	tumors	[73].	In	later	stud-
ies	it	has	been	shown	that	the	mentioned	effect	of	the	
combined	use	of	CD40	activation	and	IL-	is	related	
mainly	to	IFNγ-production.	The	authors	have	pointed	
to	an	important	fact	—	the	elevated	IFNγ	production	is	
especially	effective	at	early	stages	of	formation	of	anti-
tumor	defence,	but	at	later	ones	(at	certain	conditions)	
it	may	decrease	the	level	of	antitumor	response	[74].	
For	example,	a	pronounced	antitumor	 response	
has	been	observed	upon	 introduction	of	CD40	and	
IL-	 to	mice	with	 renal	 carcinoma	and	metastases	
whilst	therapeutic	efficacy	of	separate	administration	
of	CD40	or	IL-	was	absent	[7].
The	methods	of	 combined	application	of	 anti-
СD40-antibodies	and	irradiation	for	combined	treat-
ment	of	B-lymphoma	are	developed	[73].
Immunotherapy	with	the	use	of	CD40	and	CD40L	in	
different	variants	is	already	used	for	treatment	of	some	
oncologic	diseases	in	clinical	practice.	For	example,	in	
the	cases	of	lymphoproliferative	disorders	(leukemia,	
lymphoma,	multiple	myeloma	etc.)	it	has	been	shown	
that	binding	of	CD40	with	 its	natural	 ligand	resulted	
in	modulation	of	 transformed	B-lymphocytes	 [33].	
On	two	lymphoma	models	 it	was	demonstrated	that	
combination	of	anti-CD40-antibodies	with	irradiation	is	
accompanied	by	therapeutic	effect	mostly	expressed.	
In	the	cases	of	highly	differentiated	lymphoma,	where	
therapeutic	efficacy	depends	on	 the	doses	of	anti-
CD40-antibodies,	 doses	 of	 irradiation	 and	 tumor	
volume,	whilst	antitumor	effect	 is	mainly	 related	 to	
cytotoxic	T-lymphocytes	[75].
Therapy	with	the	use	of	CD40-stimulation	has	been	
applied	on	 the	 treatment	of	child	acute	 lymphoblas-
tic	 leukemia	[76].	The	authors	received	new	data	on	
stimulation	of	the	cells	of	bone	marrow	or	peripheral	
blood	by	CD40L	or	IL-4	showing	that	after	co-cultiva-
tion	of	leukemia	cells	with	these	stimulatory	molecules,	
expression	of	different	co-stimulatory	molecules	and	
of	antigens	MHC	classes	 I	and	 II	could	be	detected.	
CD40L-activated	leukemia	cells	acquired	an	ability	to	be	
transformed	into	dendritic	ones	and	induced	prolifera-
tion	of	allogeneic	T-lymphocytes.	These	activated	cells	
could	be	used	for	preparation	of	antitumor	vaccine.	It	
is	important	to	note	that	after	transplantation	of	these	
cells,	the	minimal	residual	effects	were	observed,	and	
the	patients	with	primary	drug	 resistance	acquired	
sensitivity	to	therapy	[74].	The	authors	supposed	that	
no	necessity	 for	gene	modification	of	 tumor	cells	 is	
an	advantage	of	such	 therapeutical	approach.	Other	
authors	share	this	opinion	[31,	77].
Discussing	the	clinical	aspects	of	CD40	use,	one	
should	 take	 into	 account	 the	data	on	elevation	of	
sCD40	 level	 in	 some	hematopoietic	malignancies	
(acute	myeloid	leukemia,	myelodysplastic	syndromes,	
chronic	lymphocytic	leukemia,	multiple	myeloma)	that	
is	associated	with	poor	prognosis,	in	particular,	in	mul-
tiple	myeloma	and	acute	myeloblastic	leukemia;	these	
facts	could	be	important	for	therapy	of	malignant	dis-
eases	of	hematopoietic	and	lymphoid	tissues	[78].
Preclinical	trials	on	therapy	of	disseminated	solid	
tumors,	non-Hodgkin’s	lymphoma	with	the	use	of	re-
combinant	CD40L	introduced	subcutaneously	at	the	
maximal	tolerated	dose	have	shown	that	such	therapy	
resulted	in	prolonged	remission	[79].
Concluding	the	presented	materials,	one	may	state	
that	the	study	of	CD40/CD40L	interaction	upon	cancer	
development	is	a	comparatively	new	discipline	that	is	
actively	developed	and	possesses	important	aspects:	
1)	widening	the	knowledge	on	interaction	of	the	cells	of	
immune	system	and	tumor	cells	with	the	involvement	
of	CD40	and	CD40L;	)	characterization	of	bilogy	of	
tumor	cells	accounting	CD40	or	CD40L	expression;	
3)	development	of	new	approaches	to	immunotherapy	
that	already	received	some	clinical	significance.
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экспрессия CD40 и CD40L на опухолевых клетках: 
роль их взаимодействия и новые подходы 
к иммунотерапии
В обзоре представлены современные данные об экспрессии CD40 и CD40L опухолевыми клетками и значении взаимодействия 
указанных молекул на этих клетках. Приведена информация о структуре и биологических свойствах этих молекул и их 
взаимодействия. Вопрос о взаимодействии CD40/CD40L рассматривали в двух аспектах — возможность ингибиции роста 
опухоли и стимуляции. В соответствии с этим изучают иммунологические механизмы, обеспечивающие торможение роста 
опухоли (роль дендритных клеток, макрофагов, моноцитов, цитотоксических Т-лимфоцитов, естественных киллеров и др.), а 
также возможность развития апоптоза. Рассматривают возможность стимуляции роста опухоли под влиянием CD40/CD40L 
взаимодействия, что отмечают в отдельных случаях. Обобщены существующие данные доступной литературы о новых 
подходах к иммунотерапии на основе анализа механизмов вышеуказанного взаимодействия.
Ключевые слова: CD40, CD40L, CD40/CD40L-взаимодействие, опухоль, иммунотерапия.
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